Tourmaline Bio's (TRML) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Tourmaline Bio (NASDAQ:TRML - Free Report) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $50.00 price target on the stock. HC Wainwright also issued estimates for Tourmaline Bio's Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.64) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.79) EPS.

A number of other analysts have also issued reports on TRML. Wedbush raised their target price on Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a report on Friday, March 14th. Chardan Capital initiated coverage on shares of Tourmaline Bio in a research note on Wednesday, April 23rd. They set a "buy" rating and a $70.00 target price for the company. Finally, Lifesci Capital initiated coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Tourmaline Bio presently has an average rating of "Buy" and an average target price of $49.33.

Tourmaline Bio Price Performance

Shares of TRML stock traded down $0.65 on Monday, hitting $15.09. The company's stock had a trading volume of 287,554 shares, compared to its average volume of 271,269. The stock has a market capitalization of $387.59 million, a price-to-earnings ratio of -5.35 and a beta of 2.11. Tourmaline Bio has a fifty-two week low of $11.56 and a fifty-two week high of $29.79. The firm's fifty day moving average price is $15.49 and its 200-day moving average price is $18.78.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.02. Analysts predict that Tourmaline Bio will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Tourmaline Bio by 7.7% in the 1st quarter. Vanguard Group Inc. now owns 1,190,810 shares of the company's stock valued at $18,112,000 after purchasing an additional 84,685 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Tourmaline Bio during the 4th quarter worth approximately $12,168,000. Velan Capital Investment Management LP grew its position in Tourmaline Bio by 28.0% in the fourth quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company's stock valued at $8,595,000 after acquiring an additional 92,605 shares during the period. Pictet Asset Management Holding SA raised its stake in Tourmaline Bio by 69.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after acquiring an additional 172,743 shares in the last quarter. Finally, Acuta Capital Partners LLC lifted its holdings in shares of Tourmaline Bio by 5.9% during the fourth quarter. Acuta Capital Partners LLC now owns 351,842 shares of the company's stock valued at $7,135,000 after acquiring an additional 19,747 shares during the period. Institutional investors and hedge funds own 91.89% of the company's stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.